Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

<< Previous

Bullboard Posts

Next >>

Post by waves1on Aug 15, 2022 6:49pm

130 Views

Post# 34897905

AGN CEO on chronic kidney disease research program

AGN CEO on the chronic kidney disease research program with NP-251/Repirinast:

https://www.youtube.com/watch?v=aMT0bnsIWPA&ab_channel=Proactive

AGN is conducting a small phase 1 study which will begin in Q4 of 2022; this study follows up on the pre-clinical animal model which showed that Repirinast reduced fibrosis by 50% with statistical significance!

This study is one of three studies that AGN is beginning in Q4 2022, the others being DMT for stroke, and Ifenprodil for pancreatic and small lung cancer.

<< Previous

Bullboard Posts

Next >>

They started in video game investing, now they serve high net worth traders